MAYNE PHARMA GROUP LIMITED
Long
Mis à jour

MYX Idea

92
-Potential right shoulder forming on a 26 week pattern thus far
-2018-01-15 with gravestone doji on weekly however makes potential boundary break on completion of pattern on the daily a little dicey
-Volume profile consistent with H&S validity thus far
-Never the less, worthy of consideration

-40 Basis point risk planned
Note
Forming ascending triangle on H4 chart, will by on break near the closing bell risking 30 Basis points in anticipation of completion of larger H&S formation
Note
snapshot
Note
Buy stop entry 0.690
30 Basis point risk
Note
Short term horizontal consolidation?
snapshot
Transaction en cours
Order filled, Long at 30 basis point risk
Note
Breakout of main pattern on high volume. Tricky to gain additional, risk/reward conscience exposure with the wide bodied bar but nevertheless, trade idea validated.
Note
I am of the opinion that Fridays move was an 'out of line move'. Being that the 'smart money' has not yet finished its accumulation phase before the rapid markup in price. Though the volume was consistent with a true break, nonetheless, we are back within the confines of the pattern which I view to still be technically strong.
However, I could always be wrong

snapshot
Note
SL moved to 0.685
Could be faced with a test of the boundary this week, Will look to add a further 50 basis points risk should we see a breakout
Stop buy order in place
Note
snapshot
Good close today, just shy of my buy order to put out my full line. I am a bit anxious of sudden rapid mark ups as I have seen in ASX equities such as ACX, MTR and SRX in the past in which I missed the train.
A good problem to have nonetheless as I have some of my position on.
Note
Order filled. Additional 50 basis points
Note
Was stopped out of secondary tranche yesterday. Remaining lot stop at 0.735

Clause de non-responsabilité

Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.